Outcomes of children exposed in utero to chemotherapy for breast cancer
Conclusions:
During the second and third trimesters, pregnant women with breast cancer can be treated with FAC safely without concerns for serious complications or short-term health concerns for their offspring who are exposed to chemotherapy in utero. Continued long-term follow-up of the children in this cohort is required.Trial registrationClinicalTrials.gov Identifier: NCT00510367. Other Study ID numbers: ID01-193, NCI-2012-01578. Registration Date: 7/31/2007 (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 30, 2014 Category: Cancer & Oncology Authors: Rashmi MurthyRichard TheriaultChad BarnettSilvia HodgeMildred RamirezAndrea MilbourneSue RimesGabriel HortobagyiVicente ValeroJennifer Litton Source Type: research
Humanization of the mouse mammary gland by replacement of the luminal layer with genetically-engineered preneoplastic human cells
Conclusions:
Injection of preneoplastic human mammary epithelial cells into the mammary ducts of immunodeficient mice leads to replacement of the murine luminal layer with morphologically normal human cells. Genetic manipulation of the injected cells makes it possible to study defined steps in the transformation of human mammary epithelial cells in a more physiological environment than has hitherto been possible. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 20, 2014 Category: Cancer & Oncology Authors: Stephanie VerbekeElodie RichardElodie MonceauXenia SchmidtBenoit RousseauValerie VelascoDavid BernardHerve BonnefoiGaetan MacGroganRichard Iggo Source Type: research
Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13
Conclusions:
Our data indicates that Pit-1 regulates MMP-1 and MMP-13, and that inhibition of MMP-13 blocked invasiveness to lung in Pit-1overexpressed breast cancer cells. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 20, 2014 Category: Cancer & Oncology Authors: Juan Sendon-LagoSamuel SeoaneNoemi EiroMaria BermudezManuel MaciaTomas Garcia-CaballeroFrancisco VizosoRoman Perez-Fernandez Source Type: research
Gene variations in oestrogen pathways, CYP19A1 , daily 17ß-estradiol and mammographic density phenotypes in premenopausal women
Conclusion:
Our findings suggest that two SNPs in CYP19A1, rs749292 and rs7172156, are associated with both daily oestrogen levels and mammographic density phenotypes. Body mass index may modify these associations, but larger studies are needed. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 19, 2014 Category: Cancer & Oncology Authors: Vidar FloteAnne-Sofie FurbergAnne McTiernanHanne FrydenbergGiske UrsinAnita IversenTrygve LofteroedPeter EllisonErik WistThore EgelandTom WilsgaardKaren MakarJenny Chang-ClaudeInger Thune Source Type: research
Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveal isoform-specific roles in mammary gland development and carcinogenesis
Conclusions:
Together, we present isoform-specific roles of ERBB4 during puberty and early pregnancy, and reveal a novel oncogenic property of CYT-1 ERBB4. The results may be exploited to develop better therapeutic strategies in breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 17, 2014 Category: Cancer & Oncology Authors: Vikram WaliMaureen Gilmore-HebertRamanaiah MamillapalliJonathan HaskinsKari KurppaKlaus EleniusCarmen BoothDavid Stern Source Type: research
Mammary cancer initiation and progression studied with magnetic resonance imaging
IntroductionPrevious work from this laboratory demonstrated that magnetic resonance imaging (MRI) detects early murine mammary cancers and reliably differentiates between in situ and invasive cancer. Based on this previous work, we used MRI to study initiation and progression of murine mammary cancer, and monitor the transition from the in situ to the invasive phase.
Methods:
In total, seven female C3(1) SV40 Tag mice were imaged every two weeks between the ages of 8 to 23?weeks. Lesions were identified on T2-weighted images acquired at 9.4 Tesla based on their morphology and growth rates. Lesions were traced manually on M...
Source: Breast Cancer Research - December 16, 2014 Category: Cancer & Oncology Authors: Xiaobing FanDevkumar MustafiErica MarkiewiczMarta ZamoraJames VosickyAbby LeinrothJeffrey MuellerKay MacleodSuzanne ConzenGregory Karczmar Source Type: research
Breast Cancer Anti-Estrogen Resistance-3 inhibits transforming growth factor-ß/Smad signaling and associates with favorable breast cancer disease outcomes
Conclusion:
BCAR3 is considered to be associated with aggressive breast cancer phenotypes. However, our results indicate that BCAR3 acts as a putative suppressor of breast cancer progression by inhibiting the pro-metastatic TGF?/Smad signaling pathway in invasive breast tumors. These data provide new insights into BCAR3?s molecular mechanism of action and highlight BCAR3 as a novel TGF?/Smad antagonist in breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 13, 2014 Category: Cancer & Oncology Authors: Jimin GuoLucie CanaffCharles RajaduraiNadège Fils-AiméJun TianMeiou DaiJuliana KorahManuel VillatoroMorag ParkSuhad AliJean-Jacques Lebrun Source Type: research
Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis
Conclusion:
BST-2 contributes to the emergence of neoplasia and malignant progression of breast cancer. Thus, BST-2 may (1) serve as a biomarker for aggressive breast cancers, and (2) be a novel target for breast cancer therapeutics. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 13, 2014 Category: Cancer & Oncology Authors: Wadie Mahauad-FernandezKris DeMaliAlicia OlivierChioma Okeoma Source Type: research
Estrogen receptor mutations and their role in breast cancer progression
Endocrine therapy is the mainstay of treatment in estrogen receptor-positive breast cancers and significantly reduces disease recurrence and breast cancer-related mortality. However, acquired resistance to therapy has been noted in nearly one-third of women treated with tamoxifen and other endocrine therapies. Mutations in the estrogen receptor have long been speculated to play a role in endocrine therapy resistance but have been rarely detected. However, recent studies utilizing next-generation sequencing on estrogen receptor-positive, metastatic clinical samples have revealed that recurrent ESR1 mutations are far more fr...
Source: Breast Cancer Research - December 12, 2014 Category: Cancer & Oncology Authors: Prasanna AlluriCorey SpeersArul Chinnaiyan Source Type: research
DEAD-box protein p68 is regulated by ß-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression
Conclusion:
Our findings indicate that Wnt/?-catenin signaling plays an important role in breast cancer progression through p68 upregulation. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 12, 2014 Category: Cancer & Oncology Authors: Kiran GuturiMoumita SarkarArijit BhowmikNilanjana DasMrinal Ghosh Source Type: research
Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study
Conclusions:
Data from this longitudinal study of EPT quitters suggest that genetic variation in two hormone metabolism pathway genes, SLCO1B1 and ARSC, may be associated with change in MD after women stop using EPT. Larger longitudinal studies are needed to confirm our findings. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 11, 2014 Category: Cancer & Oncology Authors: Eunjung LeeJianning LuoYu-Chen SuJuan LewingerFredrick SchumacherDavid Van Den BergAnna WuLeslie BernsteinGiske Ursin Source Type: research
Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor-signaling
Conclusions:
ECM1 has important roles in both cancer development and trastuzumab resistance in breast cancer through activation of EGFR signaling. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 11, 2014 Category: Cancer & Oncology Authors: Kyung-min LeeKeesoo NamSunhwa OhJuyeon LimYoung-Pil KimJong LeeJong-Han YuSei-Hyun AhnSung-Bae KimDong-Young NohTaehoon LeeIncheol Shin Source Type: research
A novel Phosphatidylinositol 3-Kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes
Conclusions:
The constitutive activation of PI3Ks and thus the exclusion of FOXO transcription factors from the nucleus is a key feature of breast cancer. Our results presented here highlight that PI3K inhibition activates specific FOXO-dependent genes that mediate cell cycle arrest in breast cancer cells. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 9, 2014 Category: Cancer & Oncology Authors: Richard HillRavi KalathurSergio CallejasLaura ColaçoRicardo BrandãoBeatriz SereldeAntonio CebriáCarmen Blanco-AparicioJoaquín PastorMatthias FutschikAna DopazoWolfgang Link Source Type: research
Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth
Conclusions:
In the present study, we reveal that progestin-induced PR activation leads to loss of GATA3 expression in breast cancer cells through transcriptional and post-translational regulation. Importantly, we demonstrate that GATA3 downregulation is required for progestin-induced upregulation of cyclin A2 and for progestin-induced in vitro and in vivo breast cancer cell growth. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 6, 2014 Category: Cancer & Oncology Authors: Franco IzzoFlorencia MercoglianoLeandro VenturuttiMercedes TkachGloria InurrigarroRoxana SchillaciLeandro CerchiettiPatricia ElizaldeCecilia Proietti Source Type: research
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Conclusions:
The HRD scores showed strong correlation with BRCA1/2 deficiency regardless of breast cancer subtype. The frequency of elevated scores suggests that a significant proportion of all breast tumor subtypes may carry defects in the homologous recombination DNA repair pathway. The HRD scores can be combined to produce a more robust predictor of HRD. The combination of a robust score, and the FFPE compatible assay described in this study, may facilitate use of agents targeting homologous recombination DNA repair in the clinical setting. (Source: Breast Cancer Research)
Source: Breast Cancer Research - December 5, 2014 Category: Cancer & Oncology Authors: Kirsten TimmsVictor AbkevichElisha HughesChris NeffJulia ReidBrian MorrisSaritha KalvaJennifer PotterThanh TranJian ChenDiana IlievZaina SangaleEliso TikishviliMichael PerryAndrey ZharkikhAlexander GutinJerry Lanchbury Source Type: research
